Clinical Trial Update: A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in participants with recurrent or primary a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Dostarlimab (dostarlimab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING